Cargando…
Viral Evolution and Immunology of SARS-CoV-2 in a Persistent Infection after Treatment with Rituximab
Background. Prolonged shedding of SARS-CoV-2 in immunocompromised patients has been described. Furthermore, an accumulation of mutations of the SARS-CoV-2 genome in these patients has been observed. Methods. We describe the viral evolution, immunologic response and clinical course of a patient with...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032773/ https://www.ncbi.nlm.nih.gov/pubmed/35458482 http://dx.doi.org/10.3390/v14040752 |
_version_ | 1784692727435231232 |
---|---|
author | Van der Moeren, Nathalie Selhorst, Philippe Ha, My Heireman, Laura Van Gaal, Pieter-Jan Breems, Dimitri Meysman, Pieter Laukens, Kris Verstrepen, Walter Van Gasse, Natasja Ogunjimi, Benson Arien, Kevin K. Naesens, Reinout |
author_facet | Van der Moeren, Nathalie Selhorst, Philippe Ha, My Heireman, Laura Van Gaal, Pieter-Jan Breems, Dimitri Meysman, Pieter Laukens, Kris Verstrepen, Walter Van Gasse, Natasja Ogunjimi, Benson Arien, Kevin K. Naesens, Reinout |
author_sort | Van der Moeren, Nathalie |
collection | PubMed |
description | Background. Prolonged shedding of SARS-CoV-2 in immunocompromised patients has been described. Furthermore, an accumulation of mutations of the SARS-CoV-2 genome in these patients has been observed. Methods. We describe the viral evolution, immunologic response and clinical course of a patient with a lymphoma in complete remission who had received therapy with rituximab and remained SARS-CoV-2 RT-qPCR positive for 161 days. Results. The patient remained hospitalised for 10 days, after which he fully recovered and remained asymptomatic. A progressive increase in Ct-value, coinciding with a progressive rise in lymphocyte count, was seen from day 137 onward. Culture of a nasopharyngeal swab on day 67 showed growth of SARS-CoV-2. Whole genome sequencing (WGS) demonstrated that the virus belonged to the wildtype SARS-CoV-2 clade 20B/GR, but rapidly accumulated a high number of mutations as well as deletions in the N-terminal domain of its spike protein. Conclusion. SARS-CoV-2 persistence in immunocompromised individuals has important clinical implications, but halting immunosuppressive therapy might result in a favourable clinical course. The long-term shedding of viable virus necessitates customized infection prevention measures in these individuals. The observed accelerated accumulation of mutations of the SARS-CoV-2 genome in these patients might facilitate the origin of new VOCs that might subsequently spread in the general community. |
format | Online Article Text |
id | pubmed-9032773 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90327732022-04-23 Viral Evolution and Immunology of SARS-CoV-2 in a Persistent Infection after Treatment with Rituximab Van der Moeren, Nathalie Selhorst, Philippe Ha, My Heireman, Laura Van Gaal, Pieter-Jan Breems, Dimitri Meysman, Pieter Laukens, Kris Verstrepen, Walter Van Gasse, Natasja Ogunjimi, Benson Arien, Kevin K. Naesens, Reinout Viruses Case Report Background. Prolonged shedding of SARS-CoV-2 in immunocompromised patients has been described. Furthermore, an accumulation of mutations of the SARS-CoV-2 genome in these patients has been observed. Methods. We describe the viral evolution, immunologic response and clinical course of a patient with a lymphoma in complete remission who had received therapy with rituximab and remained SARS-CoV-2 RT-qPCR positive for 161 days. Results. The patient remained hospitalised for 10 days, after which he fully recovered and remained asymptomatic. A progressive increase in Ct-value, coinciding with a progressive rise in lymphocyte count, was seen from day 137 onward. Culture of a nasopharyngeal swab on day 67 showed growth of SARS-CoV-2. Whole genome sequencing (WGS) demonstrated that the virus belonged to the wildtype SARS-CoV-2 clade 20B/GR, but rapidly accumulated a high number of mutations as well as deletions in the N-terminal domain of its spike protein. Conclusion. SARS-CoV-2 persistence in immunocompromised individuals has important clinical implications, but halting immunosuppressive therapy might result in a favourable clinical course. The long-term shedding of viable virus necessitates customized infection prevention measures in these individuals. The observed accelerated accumulation of mutations of the SARS-CoV-2 genome in these patients might facilitate the origin of new VOCs that might subsequently spread in the general community. MDPI 2022-04-03 /pmc/articles/PMC9032773/ /pubmed/35458482 http://dx.doi.org/10.3390/v14040752 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Van der Moeren, Nathalie Selhorst, Philippe Ha, My Heireman, Laura Van Gaal, Pieter-Jan Breems, Dimitri Meysman, Pieter Laukens, Kris Verstrepen, Walter Van Gasse, Natasja Ogunjimi, Benson Arien, Kevin K. Naesens, Reinout Viral Evolution and Immunology of SARS-CoV-2 in a Persistent Infection after Treatment with Rituximab |
title | Viral Evolution and Immunology of SARS-CoV-2 in a Persistent Infection after Treatment with Rituximab |
title_full | Viral Evolution and Immunology of SARS-CoV-2 in a Persistent Infection after Treatment with Rituximab |
title_fullStr | Viral Evolution and Immunology of SARS-CoV-2 in a Persistent Infection after Treatment with Rituximab |
title_full_unstemmed | Viral Evolution and Immunology of SARS-CoV-2 in a Persistent Infection after Treatment with Rituximab |
title_short | Viral Evolution and Immunology of SARS-CoV-2 in a Persistent Infection after Treatment with Rituximab |
title_sort | viral evolution and immunology of sars-cov-2 in a persistent infection after treatment with rituximab |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032773/ https://www.ncbi.nlm.nih.gov/pubmed/35458482 http://dx.doi.org/10.3390/v14040752 |
work_keys_str_mv | AT vandermoerennathalie viralevolutionandimmunologyofsarscov2inapersistentinfectionaftertreatmentwithrituximab AT selhorstphilippe viralevolutionandimmunologyofsarscov2inapersistentinfectionaftertreatmentwithrituximab AT hamy viralevolutionandimmunologyofsarscov2inapersistentinfectionaftertreatmentwithrituximab AT heiremanlaura viralevolutionandimmunologyofsarscov2inapersistentinfectionaftertreatmentwithrituximab AT vangaalpieterjan viralevolutionandimmunologyofsarscov2inapersistentinfectionaftertreatmentwithrituximab AT breemsdimitri viralevolutionandimmunologyofsarscov2inapersistentinfectionaftertreatmentwithrituximab AT meysmanpieter viralevolutionandimmunologyofsarscov2inapersistentinfectionaftertreatmentwithrituximab AT laukenskris viralevolutionandimmunologyofsarscov2inapersistentinfectionaftertreatmentwithrituximab AT verstrepenwalter viralevolutionandimmunologyofsarscov2inapersistentinfectionaftertreatmentwithrituximab AT vangassenatasja viralevolutionandimmunologyofsarscov2inapersistentinfectionaftertreatmentwithrituximab AT ogunjimibenson viralevolutionandimmunologyofsarscov2inapersistentinfectionaftertreatmentwithrituximab AT arienkevink viralevolutionandimmunologyofsarscov2inapersistentinfectionaftertreatmentwithrituximab AT naesensreinout viralevolutionandimmunologyofsarscov2inapersistentinfectionaftertreatmentwithrituximab |